Drug delivery
Inhaler design and development
The market for inhaled therapies continues to grow. Sales in inhalers, currently around $15billion, are predicted to rise by 18% by 2010 and new formulations mean that more therapies, for example proteins and peptides, can now be considered for delivery by the pulmonary route, in addition to existing asthma and COPD treatments.
But the realisation of a successful inhaler is an immensely complex task. For example, selecting the right technical approach for your drug, and the decision to either design your own device or to source a third party will have a major impact on project success. Also, sub-optimal product testing during development and in manufacturing can drive costs up and cause substantial program delays. Lack of a robust manufacturing strategy can further delay the launch of your product.
How can the pitfalls of inhaler development be avoided and best practice be achieved?
PA Consulting Group has a proven track record in inhaler development from concept right through to launch and can provide you with all the support you need to achieve the best possible development program.
With more than 20 years of experience of product and process development in the pharmaceutical sector, we have been at the forefront of technological innovation in the field of inhalatory medicine.
PA is able to offer the broadest possible range of services, covering every stage of a product’s development and manufacture, including:
• defining inhalation product strategy
• technology selection and audit
• market research and ‘voice of customer’ studies
• device development
• moisture protection and integrity testing
• integrating electronics
• monitoring patient compliance
• providing manufacturing solutions
• development of automated testing systems.
Contact us: For further information please e-mail: healthcare@paconsulting.com.
|
